CA3086866C - Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke - Google Patents
Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke Download PDFInfo
- Publication number
- CA3086866C CA3086866C CA3086866A CA3086866A CA3086866C CA 3086866 C CA3086866 C CA 3086866C CA 3086866 A CA3086866 A CA 3086866A CA 3086866 A CA3086866 A CA 3086866A CA 3086866 C CA3086866 C CA 3086866C
- Authority
- CA
- Canada
- Prior art keywords
- hemorrhage
- surgery
- caused
- compound
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711479490.8 | 2017-12-29 | ||
CN201711479490.8A CN109985047B (zh) | 2017-12-29 | 2017-12-29 | 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用 |
PCT/CN2018/124707 WO2019129181A1 (zh) | 2017-12-29 | 2018-12-28 | 化合物在制备治疗出血性脑卒中药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3086866A1 CA3086866A1 (en) | 2019-07-04 |
CA3086866C true CA3086866C (en) | 2022-08-16 |
Family
ID=67063234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3086866A Active CA3086866C (en) | 2017-12-29 | 2018-12-28 | Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke |
Country Status (12)
Country | Link |
---|---|
US (1) | US11382921B2 (zh) |
EP (1) | EP3733189A4 (zh) |
JP (1) | JP7007487B2 (zh) |
KR (1) | KR102475179B1 (zh) |
CN (2) | CN109985047B (zh) |
AU (1) | AU2018396897B2 (zh) |
BR (1) | BR112020013308A2 (zh) |
CA (1) | CA3086866C (zh) |
IL (1) | IL275687A (zh) |
RU (1) | RU2752090C1 (zh) |
TW (1) | TWI757573B (zh) |
WO (1) | WO2019129181A1 (zh) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783564A (en) * | 1993-12-24 | 1998-07-21 | Mitsubishi Chemical Corporation | Sialic acid derivatives |
JP3990387B2 (ja) * | 2004-06-25 | 2007-10-10 | 独立行政法人科学技術振興機構 | ヒソップ抽出物の血液流動性改善剤、血流改善剤およびその利用 |
WO2007013842A1 (en) * | 2005-07-26 | 2007-02-01 | Astrazeneca Ab | Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain |
CA2774197A1 (en) * | 2006-04-22 | 2008-04-03 | Harbor Biosciences, Inc. | Drugs and uses to modulate inflammation, metabolic disorders and other conditions |
PL2486924T3 (pl) | 2006-04-22 | 2019-07-31 | Neurmedix, Inc. | Leki i zastosowania |
CN101683348B (zh) * | 2008-09-23 | 2012-07-04 | 中山大学 | 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用 |
CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
CN101961311B (zh) * | 2010-09-21 | 2012-11-21 | 中山大学 | 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法 |
CN102180928B (zh) | 2011-03-15 | 2013-01-16 | 广州市赛普特医药科技有限公司 | 3β,5α,6β-三羟基甾体化合物及其合成方法和应用 |
WO2012138590A1 (en) * | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
CN102764280A (zh) * | 2011-05-06 | 2012-11-07 | 秦引林 | 含有牛黄,麝香的药物组合及其应用 |
KR20200057802A (ko) * | 2011-12-13 | 2020-05-26 | 노노 인코포레이티드 | 지주막하 출혈 및 허혈에 대한 치료법 |
US20140127185A1 (en) * | 2012-11-02 | 2014-05-08 | Emory University | Methods and compositions using neuroprotective steroids and thrombolytic agents |
CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
CN104288110B (zh) | 2013-06-26 | 2017-05-10 | 广州市赛普特医药科技股份有限公司 | 5α‑雄甾‑3β,5,6β‑三醇注射剂及其制备方法 |
-
2017
- 2017-12-29 CN CN201711479490.8A patent/CN109985047B/zh active Active
- 2017-12-29 CN CN202110703751.XA patent/CN113350359B/zh active Active
-
2018
- 2018-12-28 EP EP18893814.6A patent/EP3733189A4/en active Pending
- 2018-12-28 CA CA3086866A patent/CA3086866C/en active Active
- 2018-12-28 JP JP2020536200A patent/JP7007487B2/ja active Active
- 2018-12-28 AU AU2018396897A patent/AU2018396897B2/en active Active
- 2018-12-28 RU RU2020123506A patent/RU2752090C1/ru active
- 2018-12-28 US US16/958,575 patent/US11382921B2/en active Active
- 2018-12-28 BR BR112020013308-6A patent/BR112020013308A2/pt active Search and Examination
- 2018-12-28 WO PCT/CN2018/124707 patent/WO2019129181A1/zh unknown
- 2018-12-28 TW TW107147834A patent/TWI757573B/zh active
- 2018-12-28 KR KR1020207021537A patent/KR102475179B1/ko active IP Right Grant
-
2020
- 2020-06-26 IL IL275687A patent/IL275687A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW201929862A (zh) | 2019-08-01 |
RU2752090C1 (ru) | 2021-07-22 |
JP7007487B2 (ja) | 2022-01-24 |
KR102475179B1 (ko) | 2022-12-07 |
US11382921B2 (en) | 2022-07-12 |
CN109985047A (zh) | 2019-07-09 |
US20210060035A1 (en) | 2021-03-04 |
CN113350359A (zh) | 2021-09-07 |
CA3086866A1 (en) | 2019-07-04 |
EP3733189A1 (en) | 2020-11-04 |
WO2019129181A1 (zh) | 2019-07-04 |
AU2018396897A1 (en) | 2020-07-30 |
CN109985047B (zh) | 2021-07-27 |
CN113350359B (zh) | 2022-08-16 |
IL275687A (en) | 2020-08-31 |
BR112020013308A2 (pt) | 2020-12-01 |
EP3733189A4 (en) | 2021-10-20 |
KR20200104357A (ko) | 2020-09-03 |
AU2018396897B2 (en) | 2021-08-05 |
JP2021507933A (ja) | 2021-02-25 |
TWI757573B (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
US9670139B2 (en) | Telomerase activating compounds and methods of use thereof | |
ES2376793T3 (es) | Tratamiento o prevención de trastornos hipertensivos del embarazo o retraso del crecimiento fetal | |
BR112013019352A2 (pt) | método para o tratamento de lipodistrofia, uso de um composto, dosagem diária, método de tratamento, composição farmacêutica, uso da composição farmacêutica e composto | |
JP5605659B2 (ja) | 細胞保護剤 | |
US11116789B2 (en) | Compositions and methods for pain relief without numbness | |
TW201737943A (zh) | 使用fasn抑制劑之方法 | |
BR112020000989A2 (pt) | métodos e composições para tratamento de dor com o uso de capsaicina | |
JP2019522666A (ja) | 2型糖尿病の治療のためのアドレナリン受容体アゴニストの併用 | |
NO327145B1 (no) | Blanding for nasal administrasjon omfattende metansulfonat-saltet av morfin og kitosan. | |
CA3086866C (en) | Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke | |
JP2015509931A (ja) | 医薬的な組み合わせ | |
ES2423866B1 (es) | Composición farmaceútica de ibuprofeno y tramadol para inyección | |
TW201813639A (zh) | 氯硝柳胺及其衍生物的用途 | |
JP5837128B2 (ja) | カルボスチリルとカルニチンの組み合わせ医薬 | |
JP2019509321A (ja) | 疼痛を処置するための組み合わせ | |
BR112020013318A2 (pt) | uso de um composto de fórmula i ou um composto deuterado ou um sal farmaceuticamente aceitável deste na manufatura de um medicamento para o tratamento de doença de pequenos vasos cerebrais em um paciente | |
JP7219476B2 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
Mir et al. | TO INVESTIGATE THE IMPACT OF INTRATHECAL ADMINISTRATION OF DEXMEDETOMIDINE AND CLONIDINE AS ADJUVANTS AGENTS TO 0.5% HYPERBARIC BUPIVACAINE DURING SPINAL ANAESTHESIA: A COMPARATIVE STUDY | |
Zhan et al. | A Case of Severe Postop-erative Agitation and Literature Review | |
JP2024520650A (ja) | 特発性肺線維症の処置におけるカプサイシン誘導体 | |
CN103610676B (zh) | 4-((吡啶-3-羧基)-氨基)-丁酸或其盐在制备治疗男性性功能***障碍疾病药物中的应用 | |
CN117771392A (zh) | 一种gpr65激动剂和aav病毒在用于制备治疗脑缺血性疾病的药物组合上的用途及药物组合 | |
TW200800157A (en) | Alpha-2-delta ligands for non-restorative sleep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200624 |
|
EEER | Examination request |
Effective date: 20200624 |
|
EEER | Examination request |
Effective date: 20200624 |